Jefferies says Elan (ELN +6.5%) should start moving ahead of the bapineuzumab Phase 3 data,...

|About: Elan Corporation, plc (ELN)|By:, SA News Editor

Jefferies says Elan (ELN +6.5%) should start moving ahead of the bapineuzumab Phase 3 data, which the firm expects in July. Jefferies estimates a 75% of FDA approval for bapineuzumab, but believes expectations are low with little being priced into shares.